Tranexamic Acid — Discount Pricing

Other medications in Blood Disorders

• Voxelotor
• Aminocaproic Acid
• Avatrombopag
• Crizanlizumab
• Darbepoetin
• Desmopressin IV
• Eltrombopag
• Emicizumab

What Tranexamic Acid is approved for (FDA label)

Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. Tranexamic acid injection is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 29, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Tranexamic Acid (FDA label)

WARNING: RISK OF MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION ​​​​​​​Tranexamic acid injection is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when tranexamic acid injection was inadvertently administered via the neuraxial route [see Warnings and Precautions (5.1) ] . WARNING: RISK OF MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION See full prescribing information for complete boxed warning. Tranexamic acid injection is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when tranexamic acid injection was inadvertently administered intrathecally via the neuraxial route. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: fb2fcae9-6aa0-4708-b250-b0e40beb147e. SPL document ID: 5a3881b8-ac8b-a1c5-e063-6294a90a6041. Label effective date: August 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tranexamic Acid (FDA label)

Injection: 1,000 mg/10 mL (100 mg/mL) clear and colorless solution in single-dose vials Injection: 1,000 mg/10 mL (100 mg/mL) in single-dose vials ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: fb2fcae9-6aa0-4708-b250-b0e40beb147e. SPL document ID: 5a3881b8-ac8b-a1c5-e063-6294a90a6041. Label effective date: August 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tranexamic Acid (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Risk of Medication Errors Due to Incorrect Route of Administration [see Warnings and Precautions (5.1) ] Thromboembolic Risk [see Warnings and Precautions (5.2) ] Seizures [see Warnings and Precautions (5.3) ] Hypersensitivity Reactions [see Warnings and Precautions (5.4) ] Visual Disturbances [see Warnings and Precautions (5.5) ] Dizziness [see Warnings and Precautions (5.6) ] Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Milla Pharmaceuticals Inc., at 1-888-300-3908 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of tranexamic acid.

Source: FDA prescribing information (DailyMed). Set ID: fb2fcae9-6aa0-4708-b250-b0e40beb147e. SPL document ID: 5a3881b8-ac8b-a1c5-e063-6294a90a6041. Label effective date: August 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tranexamic Acid (FDA label)

Tranexamic acid injection is contraindicated: As a neuraxial (i.e., intrathecal, epidural) injection [see Warnings and Precautions (5.1) ]. ​​​ In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by tranexamic acid injection in such patients. In patients with active intravascular clotting [see Warnings and Precautions (5.2) ] . In patients with hypersensitivity to tranexamic acid or any of the ingredients [see Warnings and Precautions (5.4) ] . As a neuraxial (i.e., intrathecal, epidural) injection. ( 4 ) In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction. ( 4 ) In patients with active intravascular clotting. ( 4 ) In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: fb2fcae9-6aa0-4708-b250-b0e40beb147e. SPL document ID: 5a3881b8-ac8b-a1c5-e063-6294a90a6041. Label effective date: August 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tranexamic Acid (FDA label)

Risk of Thrombosis with Concomitant Use of Factor IX: Avoid concomitant use. ( 5.2 ) Seizures: Inadvertent injection into neuraxial system may result in seizures. ( 5.3 ) Hypersensitivity Reactions: In case of severe reaction, discontinue use and seek immediate medical attention. ( 5.4 ) Visual Disturbances: Visual or ocular adverse effects may occur. Discontinue use if visual or ocular symptoms occur. ( 5.5 ) Dizziness: Advise patients not to drive if dizziness occurs. ( 5.6 ) 5.1 Risk of Medication Errors Due to Incorrect Route of Administration Tranexamic acid injection is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when tranexamic acid injection was inadvertently administered via the neuraxial route. Confirm the correct route of administration for tranexamic acid injection and avoid confusion with other injectable solutions that might be administered at the same time as tranexamic acid injection.

Source: FDA prescribing information (DailyMed). Set ID: fb2fcae9-6aa0-4708-b250-b0e40beb147e. SPL document ID: 5a3881b8-ac8b-a1c5-e063-6294a90a6041. Label effective date: August 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tranexamic Acid (FDA label)

Prothrombotic Medical Products: Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid. ( 5.2 , 7.1 , 8.3 ) 7.1 Prothrombotic Medical Products Avoid concomitant use of tranexamic acid injection with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.2) , Use in Specific Populations (8.3) ] .

Source: FDA prescribing information (DailyMed). Set ID: fb2fcae9-6aa0-4708-b250-b0e40beb147e. SPL document ID: 5a3881b8-ac8b-a1c5-e063-6294a90a6041. Label effective date: August 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.